DME

These novel strategies may change DME treatment paradigmThere is subset of patients with resistant or persistent DME that forms the impetus for new treatment strategies, including next-generation anti-VEGF-A and new classes of drugs. Pravin U. Dugel, MD, outlines a list of potential treatment candidates that may lead that paradigm shift.
Partner Perspective: Patient Case Study - CONTINUOUS MICRODOSING™ TREATMENT WITH ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg
Sustained drug-delivery technologies shape promising futureDevelopment of technologies for sustained drug delivery is a topic of great interest among retina specialists considering the number of chronic conditions that are managed with repeated intravitreal injections.
Using OCTA in optometric practice
Using OCTA in optometric practiceBy using OCTA technology, we are able to take better care of our patients with retinal disease, make smarter referrals, or be able to hold on to our patients, knowing a referral is not needed.
Using imaging to manage diabetic retinopathy
Using imaging to manage diabetic retinopathyCreating a partnership between the optometrists and retinal practices will enhance the care of patients and serve as a continuing source of education and reference for the OD community. This constant communication will help diabetic patients who are suffering from this multifactorial disease that affects their bodies. DR must be addressed from the optometrist’s point of view, retinal specialist’s point of view, and the primary-care physician’s point of view.
Novel DME treatment derives from multimodal activityALG-1001 is an integrin receptor inhibitor that acts to stabilize the retina’s response to diabetes-related hypoxic and oxidative stress, mitigating production of a host of molecules involved in the development of diabetic macular edema.
Aflibercept helps in ME patients with DR after cataract surgeryPatients with diabetic retinopathy have a high risk of developing macular edema after cataract surgery. Intravitreal injections of aflibercept might result in fewer patients developing macular edema in this patient population.
ALG-1001: Turning off the machinery of angiogenesisALG-1001 (Luminate, Allegro Ophthalmics) has a number of different mechanisms of action that benefit patients chronically treated with anti-vascular endothelial growth factor drugs and those who are treatment naïve.
Novel therapies could stem burden of diabetic eye diseaseA better understanding of the pathophysiologic mechanisms of diabetes has resulted in improved control of its local and systemic comorbidities. Further developments are needed, however, considering the growing number of diabetic patients and who are at risk for late-stage diabetic eye disease.
Anatomic outcome more precise in defining DME treatment failureThe goal of treatment for diabetic macular edema is to maintain or improve vision, but improvement of edema is a better metric for determining whether the treatment is having a benefit or failing.
var script= ' ';